Management of cardiac implantable electronic device follow‐up in COVID‐19 pandemic: Lessons learned during Italian lockdown

Piro, Agostino; Magnocavallo, Michele; Rocca, Domenico G. Della; Neccia, Matteo; Manzi, Giovanna; Mariani, Marco Valerio; Straito, Martina; Bernardini, Alessia; Severino, Paolo; Iannucci, Gino; Giunta, Gaetano; Chimenti, Cristina; Natale, Andrea; Fedele, Francesco

doi:10.1111/jce.14755

Cited by 32 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 For these patients, inperson office visits could be replaced by remote contact, by using the device information obtained through remote monitoring (RM). 13,14 Since the beginning of the lockdown phase in Italy, Boston Scientific has communicated to all Italian centers implanting CIEDs its willingness to implement a direct home-delivery service of the LATITUDE communicator, in order to allow RM of all patients not yet monitored, without requiring access to the hospital. The initiative included delivery of the communicator, the informed consent process, and organization of remote training for patients and the staff of the center, if needed.…”

Section: Introductionmentioning

confidence: 99%

Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covid‐19 lockdown

Magnocavallo

Bernardini

Mariani

et al. 2021

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

Background During the COVID‐19 pandemic in‐person visits for patients with cardiac implantable electronic devices should be replaced by remote monitoring (RM), in order to prevent viral transmission. A direct home‐delivery service of the RM communicator has been implemented at 49 Italian arrhythmia centers. Methods According to individual patient preference or the organizational decision of the center, patients were assigned to the home‐delivery group or the standard in‐clinic delivery group. In the former case, patients received telephone training on the activation process and use of the communicator. In June 2020, the centers were asked to reply to an ad hoc questionnaire to describe and evaluate their experience in the previous 3 months. Results RM was activated in 1324 patients: 821 (62%) received the communicator at home and the communicator was activated remotely. Activation required one additional call in 49% of cases, and the median time needed to complete the activation process was 15 min [25th‐75th percentile: 10–20]. 753 (92%) patients were able to complete the correct activation of the system. At the time when the questionnaire was completed, 743 (90%) communicators were regularly transmitting data. The service was generally deemed useful (96% of respondents) in facilitating the activation of RM during the COVID‐19 pandemic and possibly beyond. Conclusions Home delivery of the communicator proved to be a successful approach to system activation, and received positive feedback from clinicians. The increased use of a RM protocol will reduce risks for both providers and patients, while maintaining high‐quality care.

show abstract

Section: Introductionmentioning

confidence: 99%

Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covid‐19 lockdown

Magnocavallo

Bernardini

Mariani

et al. 2021

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar results were observed by Piro et al in another Italian observation. However authors mention also the main challenges with the implementation of remote monitoring 43 . They are namely proper patient education, which should be performed in person and/or via telephonic contact, ensuring adoption of remote monitoring system.…”

Section: Introductionmentioning

confidence: 99%

Cardiac Resynchronization Therapy Remote Monitoring – COVID-19 Pandemic Experiences and Future Perspectives

Popiołek-Kalisz

Kalisz

2022

Current Problems in Cardiology

View full text Add to dashboard Cite

Cardiac resynchronization therapy (CRT) is a well established form of the treatment for heart failure (HF) in patients with left ventricle contraction dyssynchrony. Apart from typical in-office management, remote monitoring enables constant surveillance on both the patient's and the device's condition. This way, in case of any problems, clinical decisions could be made earlier leading to better outcome of CRT patients. COVID-19 pandemic with following lockdowns in many countries resulted in getting more attention on remote monitoring systems. The aim of this paper was to gather and summarize worldwide experiences from CRT remote monitoring during COVID-19 pandemic and point out future possibilities for HF patients treated with CRT. Already published experiences from remote monitoring of CRT devices during COVID-19 restrictions confirmed previous advantages of telemedical approach, however more publications in this area would be helpful.

show abstract

“…Moreover, the pandemic has led to a worldwide implementation of remote monitoring of cardiac implantable electronic devices, in order to reduce the in‐office device control and reduce the risk of contagion. 86 , 87 …”

Section: Role Of E‐cardiology In the Evaluation And Management Of Chronic Coronavirus Disease 2019‐linked Clinical Manifestationsmentioning

confidence: 99%

Late phase of COVID‐19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice

et al. 2021

View full text Add to dashboard Cite

Cardiovascular (CV) engagement in coronavirus disease 2019 (COVID‐19) is a huge determinant of prognosis during the acute phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID‐19 and about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myocarditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus 2 infection, and a ‘long COVID‐19’ illness has been recognized with fatigue, chest pain, and dyspnoea among the most frequent symptoms reported after discharge from hospital. This paper focuses on some open questions that cardiologists are going to face during the next months in a general cardiology outpatient clinic, in particular how to evaluate a ‘post‐COVID’ patient during follow‐up of CV complications of the acute phase and how to manage new CV symptoms that could be the consequence, at least in part, of heart/vessels and/or lung involvement of the previous virus infection. Present symptoms and signs, history of previous CV disease (both preceding COVID‐19 and occurring during viral infection), and specific laboratory and imaging measurements during the acute phase may be of interest in focusing on how to approach the clinical evaluation of a post‐COVID patient and how to integrate in our standard of care the new information on COVID‐19, possibly in a multidisciplinary view. Dealing with the increased COVID‐associated CV risk burden and becoming acquainted with potential new e‐cardiology approaches aimed at integrating the cardiology practice are relevant new challenges brought by severe acute respiratory syndrome coronavirus 2 infection and its sequelae.

show abstract

Management of cardiac implantable electronic device follow‐up in COVID‐19 pandemic: Lessons learned during Italian lockdown

Cited by 32 publications

References 17 publications

Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covid‐19 lockdown

Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covid‐19 lockdown

Cardiac Resynchronization Therapy Remote Monitoring – COVID-19 Pandemic Experiences and Future Perspectives

Late phase of COVID‐19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice

Contact Info

Product

Resources

About